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Letter 
 
Dear Sir 
 
A major limitation of cancer genomics studies has been the lack of fresh frozen tumour 
material. As massively parallel sequencing has been evolving over recent years, it has 
become feasible to sequence archival tumour material preserved as formalin-fixed paraffin 
embedded (FFPE) tissue. The oldest specimen sequenced to date is a 32 year old tumour 
sample1. Here, we set out to study the oldest retrievable specimens from the pathology 
archive of Great Ormond Street Hospital for Children (GOSH).  
 
We searched the pathology archives of GOSH, London, UK, for the oldest intact tumour 
specimens retrievable. GOSH is the oldest children’s hospital in the English speaking world. 
It was founded by Charles West in 1852 in Bloomsbury, London, from charitable donations 
raised predominantly by Charles Dickens. From paper archives (Figure 1a) we identified and 
reviewed well documented potential tumour cases from the 1920s, the earliest period for 
which both reliable reports and tissue blocks were available. We chose three different 
examples and extracted DNA using standard methods. We performed massively parallel 
sequencing on an Illumina platform targeting coding exons of 366 cancer genes by a custom 
target enrichment bait design (Agilent, USA).  
 
The quality of sequences we obtained was adequate. Compared to 96 FFPE tumour 
specimens of the last decade processed by the same pipeline, the evenness of coverage was 
unchanged. There was, however, a drop in capture efficiency in the older specimens, which 
is a known effect of age on FFPE derived DNA1. Curation of mutations revealed relevant 
driver events in each tumour. Case 1, an embryonal rhabdomyosarcoma, harboured a 
canonical NRAS Q61R mutation, which is a known driver of embryonal rhabdomyosarcoma 
(Figure 1b)2. Case 2, a lymphocytic neoplasm, was driven by a canonical mutation in 
NOTCH1, an established driver gene of haematological malignancies (Figure 1c)3. Case 3, a 
cellular capillary haemangioma, harboured an ASXL1 nonsense mutation (Figure 1d). ASXL1 
in an established cancer gene in haematological malignancies that is not known to be 
recurrently mutated in solid tumours. Interestingly, we previously identified a case with a 
truncating ASXL1 mutation in a small sequencing studies of angiosarcoma4. Thus, it may be 
possible that ASXL1 is a recurrent driver of solid vascular tumours. 
 
It is most remarkable and fortunate that FFPE preservation of tumour tissue maintains DNA 
for almost 100 years in a condition that is suitable for massively parallel sequencing. This 
paves the way for studying ultra rare tumours. Furthermore, it may enable an archaeological 
investigation into environmental mutagens of the past, the signatures of which are encoded 
in cancer genomes5.  
 
  
Figure legend 
 
Figure 1. Sequencing tumours of the past.  
 
a. Historical case register of the pathology archive of Great Ormond Street Hospital. 
 
b-d. For each case a histological section is shown. For case ‘a’  this is stained for Desmin, the 
hallmark of embryonal rhabdomyosarcoma. For cases ‘b’ and ‘c’ these are H&E stained 
slides. Underneath each section, the raw sequencing data is depicted. Reads are 
represented by blue and salmon coloured bars. The highlighted base represents the mutant 
base.  
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